Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia to Present at Wedbush PacGrow Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the 2019
View HTML
Toggle Summary Liquidia Technologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update
On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019 Continued Pipeline Progress Leveraging Proprietary PRINT® Technology Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Aug.
View HTML
Toggle Summary Liquidia to Report Second Quarter 2019 Financial Results and Provide Corporate Update on August 8, 2019
RESEARCH TRIANGLE PARK, N.C. , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT ® technology , today announced
View HTML
Toggle Summary Liquidia and GSK Restructure Collaboration Agreement
RESEARCH TRIANGLE PARK, N.C. , June 26, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology,
View HTML
Toggle Summary Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019
RESEARCH TRIANGLE PARK, N.C. , June 05, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today provided an update on the Phase 3 INSPIRE trial and development of LIQ861 for the treatment of pulmonary arterial
View HTML
Toggle Summary Liquidia to Present at Jefferies Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , June 03, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the Jefferies 2019
View HTML
Toggle Summary Liquidia Appoints Seasoned Biopharmaceutical Industry Executive Dr. Richard Katz as Chief Financial Officer
RESEARCH TRIANGLE PARK, N.C. , May 22, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced the appointment of Richard D. Katz , M.D., as Chief Financial Officer (CFO). Dr.
View HTML
Toggle Summary Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) International Conference 2019
To include highlights of the safety and tolerability of LIQ861 at two months of treatment in the INSPIRE Phase 3 Trial RESEARCH TRIANGLE PARK, N.C. , May 14, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today
View HTML
Toggle Summary Liquidia Technologies Reports First Quarter 2019 Financial Results and Provides Corporate Update
Recent Phase 3 Data Highlight Clinical Relevance of LIQ861 in Treating P ulmonary Arterial Hypertension On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019 Continued Pipeline Progress Leveraging Proprietary Print® Technology Management to Host Webcast and Conference
View HTML
Toggle Summary Liquidia Technologies to Report First Quarter 2019 Financial Results and Provide Corporate Update on May 2, 2019
RESEARCH TRIANGLE PARK, N.C. , April 23, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”),  a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML